Tripos, Continuing Reorganization, Sells Four UK Buildings | GenomeWeb
NEW YORK (GenomeWeb News) — Tripos has sold four buildings at its Bude, UK, Discovery Research location to real estate investors and Park Research, a local chemistry company, according to a Securities and Exchange Commission filing last week.
 
The move, part of Tripos’ plan to sell its chemical research units, enabled the company to recognize around $1.3 million in gross proceeds.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.